Australia markets closed
  • ALL ORDS

    7,328.00
    +2.20 (+0.03%)
     
  • AUD/USD

    0.7745
    +0.0005 (+0.06%)
     
  • ASX 200

    7,065.60
    +2.10 (+0.03%)
     
  • OIL

    63.07
    -0.06 (-0.10%)
     
  • GOLD

    1,780.20
    0.00 (0.00%)
     
  • BTC-AUD

    73,374.59
    -475.98 (-0.64%)
     
  • CMC Crypto 200

    1,293.10
    -98.61 (-7.09%)
     

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

·2-min read

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees. These inducement stock options have a grant date of February 28, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement stock options have an exercise price of $6.03 per share, the closing price of Biocept’s common stock on February 26, 2021 (which is the last date preceding the grant date on which the closing price of Biocept’s common stock was reported), are non-qualified stock options, have a ten-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service with Biocept through the applicable vesting dates. The inducement stock options are subject to the terms and conditions of Biocept’s Amended and Restated 2013 Equity Incentive Plan.

About Biocept

Biocept, Inc. is a molecular diagnostics company developing and commercializing assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ molecular diagnostic technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For additional information, please visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005253/en/

Contacts

Investor Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100